Vical Incorporated to Present Update On Pandemic Influenza Vaccine Program and Overview of Pivotal Phase 3 Melanoma Trial At ASGT Conference

SAN DIEGO, May 27, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will be presenting at a series of upcoming conferences. At the annual meeting of the American Society of Gene Therapy (San Diego, CA, May 27 - 30):